Glaucoma Concepts Shop

Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost

15.00

Category: Tag:

Description

Authors: Janet B. Serle, Jake Radell

Kugler Publications

Kugler Publications

Postal address:
P.O. Box 20538
1001 NM Amsterdam
The Netherlands
Tel: +31 20 68 45 700
www.kuglerpublications.com
info@kuglerpublications.com

© 2021 Kugler Publications.